Targeted therapies and non-small cell lung cancer: Methodological and conceptual challenge for clinical trials

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 123-129

  Perrone, Francesco ^a   Di Maio, Massimo ^a   Budillon, Alfredo ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Clinical trials; EGF R; Non small cell lung cancer; Targeted therapies

Indexed keywords

BAY 117085; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B; NAVELBINE; OBLIMERSEN; PACLITAXEL; PIVALOYLOXYMETHYL BUTYRATE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REVIEW; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 17144377557     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000155048.51919.eb     Document Type: Review

References (39)

1. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19:265-272.
2. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20:4478-4484.
3. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr Pharm Des 2002; 8:2279-2284.
4. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004; 96:990-997. A review of 60 publications of phase I studies involving new agents directed against innovative targets in oncology, with emphasis given to methodological issues like selection of patients, starting dose, dose escalation, determination of recommended dose for phase II, and correlative studies.
5. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst 2004; 96:977-978. An editorial related to [4••], where the author emphasizes strategies for the choice of end-point in phase I trials of non-cytotoxic agents.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246,
7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158. Together with [6], this is a 'proof-of-concept' phase II multicenter trial showing that gefitinib is able to induce objective responses and palliation of symptoms in patients with pretreated advanced NSCLC.
8. Cohen MH, Williams GA, Sridhara R, et al. FDA approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 2003; 8:303-306.
9. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247. A multicenter phase II study of erlotinib, showing that the drug is active and suggesting that cutaneous rash can be an important predictor of treatment efficacy.
10. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7022.
11. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109. An analysis of factors predictive of gefitinib activity showing that the drug is particularly active in patients who did never smoke and whose tumor was an adenocarcinoma with bronchioloalveolar features.
12. Lynch TJ, Beli DW, Sordella R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. N Engl J Med 2004; 350:2129-2139, References [12••, 13••, and 14••] represent the seminal papers reporting the existence of EGFR mutations and correlating them with activity of gefitinib and erlotinib.
13. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. References [12••, 13••, and 14••] represent the seminal papers reporting the existence of EGFR mutations and correlating them with activity of gefitinib and erlotinib.
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311. References [12••, 13••, and 14••] represent the seminal papers reporting the existence of EGFR mutations and correlating them with activity of gefitinib and erlotinib.
15. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167. Together with [12••], this is a paper that suggests mechanisms by which EGFR mutations may enhance transforming ability of EGFR.
16. Cappuzzo F, Gregore V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003; 21:2658-2663.
17. Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular markers to predict response to gefitinib: EGFR, Erb-B2, or more? J Clin Oncol 2004; 22:2035-2036.
18. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96:1133-1141. A retrospective study suggesting that gefitinib is more effective in patients with basal activation through phosphorylation of the AKT pathway.
19. Normanno N, Bianco C, De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:1-21.
20. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784. One of the two large multicenter phase III trials showing that the strategy of adding continuous treatment with gefitinib to standard first-line chemotherapy (cisplatin + gemcitabine in this case) does not produce any advantage in advanced NSCLC.
21. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-794. The other large multicenter phase III trial showing that the strategy of adding continuous treatment with gefitinib to standard first-line chemotherapy (paclitaxel + carboplatin in this case) does not produce any advantage in advanced NSCLC.
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7010.
23. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7011.
24. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004; 22:759-761. The editorial accompanying the publication of INTACT1 and INTACT2 results; the author discourages the strategy of performing large scale phase III trials before that preclinical models have had some confirmation in exploratory clinical trials and strongly support that correlative studies on tumor tissue are conducted within such studies.
25. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7012.
26. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191. A phase II study testing activity of bevacizumab in combination with standard chemotherapy (carboplatin + paclitaxel) as first-line treatment of advanced NSCLC.
27. Sandler AB, Blumenschein GR, Henderson T, et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22: No14S(July 15 supplement): 2000.
28. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:1760-1766.
29. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15:1187-1193. A phase II study showing that R115777 has no activity in the treatment of patients with SCLC relapsing after response to first-line chemotherapy.
30. 2/d on days 6 to 8 is a potential regimen for phase II testing in SCLC and suggesting potential activity of interest.
31. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63:7089-7093. A study showing that in mature mice a short-term treatment with a demethylating agent (5-aza-2′-deoxycytidine) particularly if combined with the histone deacetylase inhibitor sodium phenylbutyrate can significantly reduce lung tumor development.
32. Di Gennaro E, Bruzzese F, Caraglia M, et al. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 2004; 26:435-441.
33. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004; 45:381-386. A multicenter phase II trial showing that histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex) is well tolerated and has activity in patients with advanced NSCLC refractory to previous chemotherapy.
34. Reid T, Weeks A, Vakil M, et al. Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7279.
35. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136:416-425.
36. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-360. A complete review of the rationale bases and the experimental evidences for considering the proteasome a reasonable target for antineoplastic treatment, particularly to enhance sensitivity to standard chemotherapy and radiation therapy, and to overcome drug resistance.
37. Fanucchi MP, Belt RJ, Fossella FV, et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7107.
38. Davies AM, Lara PN, Lau DH, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: No 14S (July 15 supplement):7106.
39. Perrone F, De Maio M, De Maio E, et al. Statistical design in phase II clinical trials and their application in breast cancer. Lancet Oncol 2003; 4:305-311.